Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Endometrial Cancer | Research

Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer

Authors: Rui Shi, Haojia Li, Sitian Wei, Zhicheng Yu, Jun Zhang, Qi Zhang, Ting Zhou, Yuwei Yao, Qian Zhang, Tangansu Zhang, Hongbo Wang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Metabolic reprogramming is one of hallmarks of cancer progression and is of great importance for the tumor microenvironment (TME). As an abundant metabolite, lactate has been found to play a critical role in cancer development and immunosuppression of TME. However, the potential role of lactate metabolism-related genes in endometrial cancer (EC) remains obscure.

Methods

RNA sequencing data and clinical information of EC were obtained from The Cancer Genome Atlas (TCGA) database. Lactate metabolism-related genes (LMRGs) WERE from Molecular Signature Database v7.4 and then compared the candidate genes from TCGA to obtain final genes. Univariate analysis and Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression were performed to screen prognostic genes. A lactate metabolism-related risk profile was constructed using multivariate Cox regression analysis. The signature was validated by time-dependent ROC curve analysis and Kaplan-Meier analysis. The relationship between the risk score and age, grade, stage, tumor microenvironmental characteristics, and drug sensitivity was as well explored by correlation analyses. Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway functional analysis between the high and low-risk groups were performed. CCK8, EdU, and clone formation assays were applied to detect the proliferation ability of EC cells, Transwell assay was performed to detect the migration ability of EC cells, and intracellular lactate and glucose content was used to asses lactate metabolism.

Results

We constructed a risk signature based on 18 LMRGs. Kaplan-Meier curves confirmed that the high-risk group had poorer prognosis compared to the low-risk group. A nomogram was then constructed to predict the probability of EC survival. We also performed GO enrichment analysis and KEGG pathway functional analysis between the high and low-risk groups, and the outcome revealed that the features were significantly associated with energy metabolism. There was a significant correspondence between LMRGs and tumor mutational load, checkpoints and immune cell infiltration. C1, C2, and C4 were the most infiltrated in the high-risk group. The high-risk group showed increased dendritic cell activation, while the low-risk group showed increased plasma cells and Treg cells. Drug sensitivity analysis showed LMRGs risk was more resistant to Scr kinase inhibitors. We further proved that one of the lactate metabolism related genes, TIMM50 could promote EC cell proliferation, migration and lactate metabolism.

Conclusion

In conclusion, we have established an effective prognostic signature based on LMRG expression patterns, which may greatly facilitate the assessment of prognosis, molecular features and treatment modalities in EC patients and may be useful in the future translation to clinical applications. TIMM50 was identified as a novel molecule that mediates lactate metabolism in vitro and in vivo, maybe a promising target for EC prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H. et.al, global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef Sung H. et.al, global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
go back to reference Crosbie EJ. et al Endometrial cancer Lancet. 2022;399(10333):1412–28. Crosbie EJ. et al Endometrial cancer Lancet. 2022;399(10333):1412–28.
3.
go back to reference Clarke MA. et.al, Association of Endometrial Cancer Risk with postmenopausal bleeding in women: a systematic review and Meta-analysis. JAMA Intern Med. 2018;178(9):1210–22.PubMedPubMedCentralCrossRef Clarke MA. et.al, Association of Endometrial Cancer Risk with postmenopausal bleeding in women: a systematic review and Meta-analysis. JAMA Intern Med. 2018;178(9):1210–22.PubMedPubMedCentralCrossRef
4.
go back to reference Reed N. et.al, british Gynaecological Cancer Society (BGCS) cervical cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2021;256:433–65.PubMedCrossRef Reed N. et.al, british Gynaecological Cancer Society (BGCS) cervical cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2021;256:433–65.PubMedCrossRef
6.
go back to reference Chiaradonna F. From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv. 2012;30(1):30–51.PubMedCrossRef Chiaradonna F. From cancer metabolism to new biomarkers and drug targets. Biotechnol Adv. 2012;30(1):30–51.PubMedCrossRef
8.
go back to reference Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–37.PubMedCrossRef Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–37.PubMedCrossRef
9.
go back to reference Ji LJ. et.al, worenine reverses the Warburg effect and inhibits colon cancer cell growth by negatively regulating HIF-1α. Cell Mol Biol Lett. 2021;26(1):19.PubMedPubMedCentralCrossRef Ji LJ. et.al, worenine reverses the Warburg effect and inhibits colon cancer cell growth by negatively regulating HIF-1α. Cell Mol Biol Lett. 2021;26(1):19.PubMedPubMedCentralCrossRef
10.
go back to reference Chen XY. Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis. J Pineal Res. 2021;71(2):e12755.PubMedCrossRef Chen XY. Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis. J Pineal Res. 2021;71(2):e12755.PubMedCrossRef
11.
go back to reference Xu K, Yin N, Peng M, Efstathios G, Stamatiades A, Shyu P, Li. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science. 2021;371(6527):405–10.PubMedPubMedCentralCrossRef Xu K, Yin N, Peng M, Efstathios G, Stamatiades A, Shyu P, Li. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science. 2021;371(6527):405–10.PubMedPubMedCentralCrossRef
12.
go back to reference Han X, Ren C, Yang T, Qiao P, Wang L, Jiang A. Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer. Oncogene. 2019;38(38):6537–49.PubMedCrossRef Han X, Ren C, Yang T, Qiao P, Wang L, Jiang A. Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer. Oncogene. 2019;38(38):6537–49.PubMedCrossRef
13.
go back to reference George A, Brooks. Lactate as a fulcrum of metabolism. Redox Biol. 2020;35:101454.CrossRef George A, Brooks. Lactate as a fulcrum of metabolism. Redox Biol. 2020;35:101454.CrossRef
14.
go back to reference Shiren S, Li H, Chen J, Qian Q. Lactic acid: no longer an Inert and End-Product of Glycolysis. Physiol (Bethesda). 2017;32(6):453–63. Shiren S, Li H, Chen J, Qian Q. Lactic acid: no longer an Inert and End-Product of Glycolysis. Physiol (Bethesda). 2017;32(6):453–63.
15.
go back to reference Gu J. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. Cell Rep. 2022;39(12):110986.PubMedCrossRef Gu J. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. Cell Rep. 2022;39(12):110986.PubMedCrossRef
16.
go back to reference Ippolito LG. et.al, lactate: a metabolic driver in the Tumour Landscape. Trends Biochem Sci. 2019;44(2):153–66.PubMedCrossRef Ippolito LG. et.al, lactate: a metabolic driver in the Tumour Landscape. Trends Biochem Sci. 2019;44(2):153–66.PubMedCrossRef
17.
go back to reference Zhang A. et.al, lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. Theranostics. 2021;11(8):3839–52.PubMedPubMedCentralCrossRef Zhang A. et.al, lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17. Theranostics. 2021;11(8):3839–52.PubMedPubMedCentralCrossRef
18.
go back to reference Deng HJ. et.al, tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer. 2021;9(6):e002305.PubMedPubMedCentralCrossRef Deng HJ. et.al, tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer. 2021;9(6):e002305.PubMedPubMedCentralCrossRef
19.
go back to reference Liberzon A. et.al, Molecular signatures database (MSigDB) 3.0. Bioinformatics, 2011. 27(12): p. 1739–40. Liberzon A. et.al, Molecular signatures database (MSigDB) 3.0. Bioinformatics, 2011. 27(12): p. 1739–40.
20.
21.
go back to reference Liu ZQ. Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer. Cancer Cell Int. 2021;21(1):359.PubMedPubMedCentralCrossRef Liu ZQ. Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer. Cancer Cell Int. 2021;21(1):359.PubMedPubMedCentralCrossRef
22.
go back to reference Liu ZQ. et.al, clinical significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune signature in Stage II/III Colorectal Cancer. Front Immunol. 2021;12:702594.PubMedPubMedCentralCrossRef Liu ZQ. et.al, clinical significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune signature in Stage II/III Colorectal Cancer. Front Immunol. 2021;12:702594.PubMedPubMedCentralCrossRef
23.
go back to reference He QF, Yang J, Jin YH. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma. Brief Bioinform. 2022;23(4):bbac291.PubMedCrossRef He QF, Yang J, Jin YH. Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma. Brief Bioinform. 2022;23(4):bbac291.PubMedCrossRef
24.
go back to reference Iasonos A. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.PubMedCrossRef Iasonos A. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.PubMedCrossRef
25.
go back to reference Vésteinn T. et.al, the Immune Landscape of Cancer. Immunity. 2019;51(2):411–2.CrossRef Vésteinn T. et.al, the Immune Landscape of Cancer. Immunity. 2019;51(2):411–2.CrossRef
26.
go back to reference Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014;15(3):R47.PubMedPubMedCentralCrossRef Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014;15(3):R47.PubMedPubMedCentralCrossRef
27.
go back to reference Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.PubMedPubMedCentralCrossRef Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.PubMedPubMedCentralCrossRef
28.
go back to reference Minoru K. et.al, KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.CrossRef Minoru K. et.al, KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.CrossRef
30.
go back to reference Tang R. et.al, ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Brief Bioinform. 2022;23(1):bbab388.PubMedCrossRef Tang R. et.al, ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma. Brief Bioinform. 2022;23(1):bbab388.PubMedCrossRef
31.
32.
go back to reference Certo M. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–61.PubMedCrossRef Certo M. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat Rev Immunol. 2021;21(3):151–61.PubMedCrossRef
33.
go back to reference Ippolito LG. et.al, lactate: a metabolic driver in the Tumour Landscape. Trends Biochem Sci. 2019;44(2):153–66.PubMedCrossRef Ippolito LG. et.al, lactate: a metabolic driver in the Tumour Landscape. Trends Biochem Sci. 2019;44(2):153–66.PubMedCrossRef
34.
go back to reference Wang X, et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. Thorac Cancer. 2019;10(6):1395–401.PubMedPubMedCentralCrossRef Wang X, et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. Thorac Cancer. 2019;10(6):1395–401.PubMedPubMedCentralCrossRef
35.
go back to reference Zhang Z, et al. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Cancer Med. 2019;8(4):1467–73.PubMedPubMedCentralCrossRef Zhang Z, et al. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Cancer Med. 2019;8(4):1467–73.PubMedPubMedCentralCrossRef
36.
go back to reference Schouwenburg MG, et al. Switching to immune checkpoint inhibitors upon response to targeted therapy; the road to long-term survival in advanced melanoma patients with highly elevated serum LDH? Cancers (Basel). 2019;11(12):1940.PubMedCrossRef Schouwenburg MG, et al. Switching to immune checkpoint inhibitors upon response to targeted therapy; the road to long-term survival in advanced melanoma patients with highly elevated serum LDH? Cancers (Basel). 2019;11(12):1940.PubMedCrossRef
37.
go back to reference Phillip MGJ, Zang XX, Zheng DY. Molecular features of Cancer-associated fibroblast subtypes and their implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. Clin Cancer Res. 2021;27(9):2636–47.CrossRef Phillip MGJ, Zang XX, Zheng DY. Molecular features of Cancer-associated fibroblast subtypes and their implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance. Clin Cancer Res. 2021;27(9):2636–47.CrossRef
38.
go back to reference Lheureux S. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunotherapy Cancer. 2022;10(3):e004233.CrossRef Lheureux S. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunotherapy Cancer. 2022;10(3):e004233.CrossRef
40.
go back to reference Huang YX. Et. al, Leptin promotes the migration and invasion of breast cancer cells by upregulating ACAT2. Cell Oncol (Dordr). 2017;40(6):537–47.PubMedCrossRef Huang YX. Et. al, Leptin promotes the migration and invasion of breast cancer cells by upregulating ACAT2. Cell Oncol (Dordr). 2017;40(6):537–47.PubMedCrossRef
41.
go back to reference Weng ML. Et. al, ACAT2 promotes cell proliferation and associates with malignant progression in Colorectal Cancer. Oncol Targets and Therapy. 2020;13:3477–88.CrossRef Weng ML. Et. al, ACAT2 promotes cell proliferation and associates with malignant progression in Colorectal Cancer. Oncol Targets and Therapy. 2020;13:3477–88.CrossRef
42.
go back to reference Bu PC. Et. al, aldolase B-Mediated Fructose Metabolism drives metabolic reprogramming of Colon Cancer Liver Metastasis. Cell Metabol. 2018;27(6):1249–62.CrossRef Bu PC. Et. al, aldolase B-Mediated Fructose Metabolism drives metabolic reprogramming of Colon Cancer Liver Metastasis. Cell Metabol. 2018;27(6):1249–62.CrossRef
43.
go back to reference Liu GJ. Fructose-1,6-Bisphosphate Aldolase B Depletion promotes Hepatocellular Carcinogenesis through activating insulin receptor signaling and lipogenesis. Hepatology. 2021;74(6):3037–55.PubMedCrossRef Liu GJ. Fructose-1,6-Bisphosphate Aldolase B Depletion promotes Hepatocellular Carcinogenesis through activating insulin receptor signaling and lipogenesis. Hepatology. 2021;74(6):3037–55.PubMedCrossRef
44.
go back to reference Zhao J. Integrative analysis of bulk RNA-Seq and single-cell RNA-Seq unveils novel prognostic biomarkers in multiple myeloma. Biomolecules. 2022;12(12):1855.PubMedPubMedCentralCrossRef Zhao J. Integrative analysis of bulk RNA-Seq and single-cell RNA-Seq unveils novel prognostic biomarkers in multiple myeloma. Biomolecules. 2022;12(12):1855.PubMedPubMedCentralCrossRef
45.
go back to reference Castracani CC et al. Role of 17 β-Estradiol on Cell Proliferation and Mitochondrial Fitness in Glioblastoma Cells. Journal of oncology, 2020. 2020: p. 2314693. Castracani CC et al. Role of 17 β-Estradiol on Cell Proliferation and Mitochondrial Fitness in Glioblastoma Cells. Journal of oncology, 2020. 2020: p. 2314693.
46.
go back to reference Zhang XP, et.al. TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients. Mol Carcinog. 2019;58(5):767–76.PubMedCrossRef Zhang XP, et.al. TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients. Mol Carcinog. 2019;58(5):767–76.PubMedCrossRef
47.
go back to reference Sankala H. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys. 2011;512(1):52–60.PubMedPubMedCentralCrossRef Sankala H. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys. 2011;512(1):52–60.PubMedPubMedCentralCrossRef
48.
go back to reference Gao SP. et.al, loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer. Tumour Biol. 2016;37(1):1279–87.PubMedCrossRef Gao SP. et.al, loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer. Tumour Biol. 2016;37(1):1279–87.PubMedCrossRef
Metadata
Title
Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer
Authors
Rui Shi
Haojia Li
Sitian Wei
Zhicheng Yu
Jun Zhang
Qi Zhang
Ting Zhou
Yuwei Yao
Qian Zhang
Tangansu Zhang
Hongbo Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10934-y

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine